$NKTR
Nektar Therapeutics

2016 Q4 Form 10-Q Financial Statement

#000156459016027488 Filed on November 04, 2016

View on sec.gov

Income Statement

Concept 2016 Q4 2015 Q3
Revenue $37.45M $59.95M
YoY Change -4.88% -54.88%
Cost Of Revenue $6.604M $6.760M
YoY Change -21.04% -26.68%
Gross Profit $30.85M $53.19M
YoY Change -0.52% -56.98%
Gross Profit Margin 82.37% 88.72%
Selling, General & Admin $12.80M $9.500M
YoY Change -3.03% 4.4%
% of Gross Profit 41.5% 17.86%
Research & Development $50.23M $43.23M
YoY Change 6.57% 26.4%
% of Gross Profit 162.85% 81.27%
Depreciation & Amortization $3.900M $3.300M
YoY Change 2.63% 3.13%
% of Gross Profit 12.64% 6.2%
Operating Expenses $50.23M $43.23M
YoY Change 6.57% 26.4%
Operating Profit -$32.15M $419.0K
YoY Change 9.47% -99.48%
Interest Expense -$9.600M $4.202M
YoY Change -10.28% -4.3%
% of Operating Profit 1002.86%
Other Income/Expense, Net -$8.530M
YoY Change -9.91%
Pretax Income -$41.80M -$8.111M
YoY Change -22.74% -111.45%
Income Tax $400.0K $92.00K
% Of Pretax Income
Net Earnings -$42.20M -$8.203M
YoY Change -22.05% -111.62%
Net Earnings / Revenue -112.68% -13.68%
Basic Earnings Per Share -$0.28 -$0.06
Diluted Earnings Per Share -$0.28 -$0.06
COMMON SHARES
Basic Shares Outstanding 152.8M 132.6M shares
Diluted Shares Outstanding 132.6M shares

Balance Sheet

Concept 2016 Q4 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $389.1M $267.8M
YoY Change 25.96% 13.19%
Cash & Equivalents $59.64M $18.82M
Short-Term Investments $329.5M $249.0M
Other Short-Term Assets $10.36M $5.214M
YoY Change 5.59% 10.75%
Inventory $11.11M $10.35M
Prepaid Expenses
Receivables $15.68M $2.966M
Other Receivables $0.00 $0.00
Total Short-Term Assets $426.3M $286.4M
YoY Change 21.77% -11.65%
LONG-TERM ASSETS
Property, Plant & Equipment $65.60M $72.53M
YoY Change -8.04% 4.7%
Goodwill $76.50M $76.50M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $817.0K $13.86M
YoY Change 8.36% 97.86%
Total Long-Term Assets $142.6M $162.9M
YoY Change -4.02% 6.62%
TOTAL ASSETS
Total Short-Term Assets $426.3M $286.4M
Total Long-Term Assets $142.6M $162.9M
Total Assets $568.9M $449.2M
YoY Change 14.08% -5.8%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.816M $2.279M
YoY Change 19.17% -58.01%
Accrued Expenses $35.10M $43.60M
YoY Change 55.31% 461.86%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $5.900M
YoY Change
Total Short-Term Liabilities $72.22M $208.1M
YoY Change 17.92% 158.35%
LONG-TERM LIABILITIES
Long-Term Debt $243.5M $1.300M
YoY Change 0.29% -99.0%
Other Long-Term Liabilities $5.000M $10.67M
YoY Change -48.67% -30.71%
Total Long-Term Liabilities $5.000M $10.67M
YoY Change -48.67% -30.71%
TOTAL LIABILITIES
Total Short-Term Liabilities $72.22M $208.1M
Total Long-Term Liabilities $5.000M $10.67M
Total Liabilities $480.7M $410.2M
YoY Change -2.33% -4.54%
SHAREHOLDERS EQUITY
Retained Earnings -$2.021B -$1.813B
YoY Change 8.22% 4.18%
Common Stock $2.111B $1.854B
YoY Change 12.55% 3.64%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $88.13M $39.05M
YoY Change
Total Liabilities & Shareholders Equity $568.9M $449.2M
YoY Change 14.08% -5.8%

Cashflow Statement

Concept 2016 Q4 2015 Q3
OPERATING ACTIVITIES
Net Income -$42.20M -$8.203M
YoY Change -22.05% -111.62%
Depreciation, Depletion And Amortization $3.900M $3.300M
YoY Change 2.63% 3.13%
Cash From Operating Activities -$52.40M -$14.10M
YoY Change -30.23% -69.35%
INVESTING ACTIVITIES
Capital Expenditures -$2.700M -$4.100M
YoY Change 8.0% 355.56%
Acquisitions
YoY Change
Other Investing Activities -$139.4M $9.900M
YoY Change 2865.96% -75.85%
Cash From Investing Activities -$142.1M $5.700M
YoY Change 1873.61% -85.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $189.7M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 190.9M 6.400M
YoY Change 60.29% -11.11%
NET CHANGE
Cash From Operating Activities -52.40M -14.10M
Cash From Investing Activities -142.1M 5.700M
Cash From Financing Activities 190.9M 6.400M
Net Change In Cash -3.600M -2.000M
YoY Change -109.78% -253.85%
FREE CASH FLOW
Cash From Operating Activities -$52.40M -$14.10M
Capital Expenditures -$2.700M -$4.100M
Free Cash Flow -$49.70M -$10.00M
YoY Change -31.54% -77.83%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
55570000
CY2015Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
19947000
CY2015Q4 us-gaap Inventory Net
InventoryNet
11346000
us-gaap Operating Income Loss
OperatingIncomeLoss
-7000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
30031000
us-gaap Interest Expense
InterestExpense
12491000
nktr Non Cash Interest Expense Related To Sale Of Royalties
NonCashInterestExpenseRelatedToSaleOfRoyalties
15428000
nktr Non Cash Royalty Revenue Related To Sale Of Future Royalties
NonCashRoyaltyRevenueRelatedToSaleOfFutureRoyalties
14752000
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
26182000
us-gaap Royalty Revenue
RoyaltyRevenue
1057000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
135652000
us-gaap Costs And Expenses
CostsAndExpenses
191421000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1355000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-26564000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-26571000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
469000
us-gaap Net Income Loss
NetIncomeLoss
-27040000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27294000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14499000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
131882000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
9109000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
1448000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-641000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-2600000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-3843000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-525000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
7056000
nktr Increase Decrease In Accrued Clinical Trial Expenses
IncreaseDecreaseInAccruedClinicalTrialExpenses
3394000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
949000
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
-3750000
nktr Increase Decrease In Refundable Upfront Payment Liabilities
IncreaseDecreaseInRefundableUpfrontPaymentLiabilities
0
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
3854000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
2026000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
202870000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
155683000
us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
23778000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3741000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
59705000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
5376000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
18041000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
12665000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-32000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
7725000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12365000
us-gaap Interest Paid
InterestPaid
15513000
nktr Debt Investment Maximum Maturity Period
DebtInvestmentMaximumMaturityPeriod
Two years or less
nktr Debt Investment Maturity Date Description
DebtInvestmentMaturityDateDescription
One year or less
CY2016Q3 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
5000000
CY2015Q3 us-gaap Proceeds From Sale Of Available For Sale Securities
ProceedsFromSaleOfAvailableForSaleSecurities
18600000
CY2016Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
187286000
CY2015Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
250444000
CY2016Q3 nktr Cash And Restricted Cash
CashAndRestrictedCash
1203000
CY2015Q4 nktr Cash And Restricted Cash
CashAndRestrictedCash
1842000
CY2016Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2015Q3 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
1031573
us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
2507701
us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
2000823
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
152835294
CY2015Q4 us-gaap Available For Sale Securities Current
AvailableForSaleSecuritiesCurrent
253374000
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
9814000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
350051000
CY2015Q4 nktr Liability Related To Sale Of Potential Future Royalties Non Current
LiabilityRelatedToSaleOfPotentialFutureRoyaltiesNonCurrent
116029000
nktr Increase Decrease In Refundable Upfront Payment Liabilities
IncreaseDecreaseInRefundableUpfrontPaymentLiabilities
12500000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-11832000
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
0
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-25000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8722000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-7131000
us-gaap Repayments Of Long Term Capital Lease Obligations
RepaymentsOfLongTermCapitalLeaseObligations
3798000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
15516000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
11718000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-159000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
6454000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18819000
us-gaap Interest Paid
InterestPaid
16095000
nktr Non Cash Transaction Accrued Debt Issuance Costs
NonCashTransactionAccruedDebtIssuanceCosts
0
nktr Non Cash Transaction Accrued Debt Issuance Costs
NonCashTransactionAccruedDebtIssuanceCosts
8503000
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Accounting estimates and assumptions are inherently uncertain. Actual results could differ materially from those estimates and assumptions. Our estimates include those related to estimated selling prices of deliverables in collaboration agreements, estimated periods of performance, the net realizable value of inventory, the impairment of investments, the impairment of goodwill and long-lived assets, contingencies, accrued clinical trial expenses, estimated non-cash royalty revenue and interest expense from our liability related to our sale of future royalties, stock-based compensation, and ongoing litigation, among other estimates. We base our estimates on historical experience and on other assumptions that management believes are reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. As appropriate, estimates are assessed each period and updated to reflect current information and any changes in estimates will generally be reflected in the period first identified.</p></div>
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reclassifications</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Certain items previously reported in specific financial statement captions have been reclassified to conform to the current period presentation, including as a result of the adoption of new accounting guidance related to debt issuance costs described below.&nbsp;&nbsp;Such reclassifications do not materially impact previously reported revenue, operating income (loss), net income (loss), total assets, liabilities or stockholders&#8217; equity (deficit). </p></div>
CY2016Q3 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
253511000
CY2016Q3 us-gaap Senior Notes
SeniorNotes
250000000
CY2016Q3 us-gaap Debt And Capital Lease Obligations
DebtAndCapitalLeaseObligations
254500000
CY2016Q3 us-gaap Capital Lease Obligations
CapitalLeaseObligations
4500000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2015Q4 nktr Cash Restricted Cash Cash Equivalents And Available For Sale Investments
CashRestrictedCashCashEquivalentsAndAvailableForSaleInvestments
308944000
CY2015Q3 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2016Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2015Q3 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2016Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
2386000
CY2015Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
3236000
CY2016Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
6695000
CY2015Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
6087000
CY2016Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
1673000
CY2015Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
2023000
nktr Estimated Annual Interest Rate On Royalty Liability
EstimatedAnnualInterestRateOnRoyaltyLiability
0.17
nktr Royalty Agreement Contingent Payment Description
RoyaltyAgreementContingentPaymentDescription
as a result of worldwide net sales of MIRCERA® for the 12 month periods ended December 31, 2013 and 2012 not reaching certain minimum thresholds.
CY2015Q3 nktr Damage Claim For Alleged Unpaid Licensing Fee
DamageClaimForAllegedUnpaidLicensingFee
1500000
nktr Potential Development Milestones
PotentialDevelopmentMilestones
147000000
CY2016Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6166000
CY2015Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4762000
CY2016Q3 us-gaap Stock Issued During Period Shares Share Based Compensation
StockIssuedDuringPeriodSharesShareBasedCompensation
1193764

Files In Submission

Name View Source Status
0001564590-16-027488-index-headers.html Edgar Link pending
0001564590-16-027488-index.html Edgar Link pending
0001564590-16-027488.txt Edgar Link pending
0001564590-16-027488-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
nktr-10q_20160930.htm Edgar Link pending
nktr-20160930.xml Edgar Link completed
nktr-20160930.xsd Edgar Link pending
nktr-20160930_cal.xml Edgar Link unprocessable
nktr-20160930_def.xml Edgar Link unprocessable
nktr-20160930_lab.xml Edgar Link unprocessable
nktr-20160930_pre.xml Edgar Link unprocessable
nktr-ex101_8.htm Edgar Link pending
nktr-ex311_9.htm Edgar Link pending
nktr-ex312_7.htm Edgar Link pending
nktr-ex321_6.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending